Phase 2 Start
CGEM: Phase 2 Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refrac
December 1, 2026 · velinotamig. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- Cullinan Therapeutics, Inc. (CGEM)
- Drug
- velinotamig
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refrac
- Drug
- velinotamig
- Indication
- Immune Thrombocytopenia (ITP); Warm Autoimmune Hemolytic Anemia (WAIHA)